Get the Stockscreener App
23.48
3.71%
0.84
After Hours:
23.55
0.07
+0.30%
Immunome Inc stock is traded at $23.48, with a volume of 3.47M.
It is up +3.71% in the last 24 hours and up +36.99% over the past month.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
See More
Previous Close:
$22.64
Open:
$22.88
24h Volume:
3.47M
Relative Volume:
2.12
Market Cap:
$2.15B
Revenue:
$12.59M
Net Income/Loss:
$-212.39M
P/E Ratio:
-7.6103
EPS:
-3.0853
Net Cash Flow:
$-185.92M
1W Performance:
+23.19%
1M Performance:
+36.99%
6M Performance:
+146.12%
1Y Performance:
+88.75%
1-Day Range:
$22.60
$24.07
1-Week Range:
$18.81
$25.30
52-Week Range:
$5.1501
$25.30
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
23.48 | 2.08B | 12.59M | -212.39M | -185.92M | -3.0853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.96 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.36 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
851.42 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.17 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
200.67 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-01-25 | Initiated | Truist | Buy |
| Sep-22-25 | Initiated | Goldman | Buy |
| Sep-05-25 | Initiated | Craig Hallum | Buy |
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Immunome Announces Pricing of Public Offering of Common Stock - pharmiweb.com
IMNM Stock Offering Priced Below Previous Close - GuruFocus
Immunome announces pricing of public offering of 18,625,000 shares at $21.50 each - marketscreener.com
Immunome prices public offering of common stock at $21.50 per share - Investing.com Australia
Immunome prices public offering of common stock at $21.50 per share By Investing.com - Investing.com South Africa
Biotech Immunome moves ahead with $400M common stock sale - Stock Titan
IMNM Sees Boost in Price Target from Lake Street Analyst | IMNM Stock News - GuruFocus
Immunome price target raised to $35 from $25 at Guggenheim - TipRanks
IMNM: Guggenheim Raises Price Target to $35, Maintains Buy Ratin - GuruFocus
Evercore ISI Group Raises Price Target for Immunome (IMNM) to $4 - GuruFocus
Evercore ISI Issues Positive Forecast for Immunome (NASDAQ:IMNM) Stock Price - MarketBeat
Immunome stock price target raised to $35 by Guggenheim on positive trial data - Investing.com India
Immunome up 16% on varegacestat Phase III results in desmoid tumors - The Pharma Letter
Immunome (IMNM) Valuation After Breakthrough Phase 3 RINGSIDE Results and Planned FDA New Drug Application - Yahoo Finance
Immunome seeks GSI inhibitor market entry on Phase III desmoid tumour win - Yahoo Finance
Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025) - ts2.tech
Evercore ISI raises Immunome stock price target to $40 on positive trial data - Investing.com
Immunome plans to offer $400 million in common stock shares By Investing.com - Investing.com Australia
Immunome (IMNM) Is Up 15.3% After Desmoid Tumor Phase 3 Win and NDA Timeline Update – Has The Bull Case Changed? - simplywall.st
Immunome, a top 3% stock, just delivered a 'knockout' to Merck KGaA - MSN
Immunome Soars 15% as Phase 3 Trial of Desmoid Tumor Drug Achieves Overwhelming Success - NAI500
Cryptocurrencies, White House’s Tech Force, and Immunome: Stock Market News - thestreet.com
Why Immunome Stock Surged Today - sharewise.com
Immunome’s Phase III Varegacestat Data Show Best-In-Class Potential In Desmoid Tumors - Citeline News & Insights
Immunome’s Promising Outlook: Buy Rating Affirmed on Varegacestat’s Phase 3 Success and Strong Management - TipRanks
Immunome announces proposed public offering - MSN
IMNM: Key Managers Appointed for Upcoming Stock Offering - GuruFocus
The 'Knockout' Hit That Sent This Top 3% Biotech Stock Flying - Investor's Business Daily
Immunome Plans $400 Million Public Stock Offering - marketscreener.com
Immunome announces proposed public offering of common stock - marketscreener.com
Immunome Announces Proposed Public Offering of Common Stock - Yahoo Finance
Immunome Stock Surges 20% After Positive Phase 3 Data For Desmoid Tumor Drug - Nasdaq
Top Biotech Stocks To ConsiderDecember 15th - MarketBeat
Stocks making the biggest moves midday: Zillow, KLA, iRobot, Immunome & more - CNBC
Immunome (NASDAQ:IMNM) Shares Gap UpStill a Buy? - MarketBeat
Immunome’s desmoid tumor drug shows 84% reduction in disease progression - Investing.com Nigeria
Immunome jumps after promising results for its desmoid tumor treatment - marketscreener.com
Ringside sends Immunome towards filing | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Immunome’s Varegacestat Shines in Phase 3 RINGSIDE Trial, Earning Buy Rating from Charles Zhu - TipRanks
Here’s Why Immunome Stock (IMNM) Soared Over 20% Today - TipRanks
Wedbush Adjusts Immunome Price Target to $31 From $21, Maintains Outperform Rating - marketscreener.com
Immunome Target of Unusually High Options Trading (NASDAQ:IMNM) - MarketBeat
Kyverna Therapeutics, Immunome, Almonty Industries And Other Big Stocks Moving Higher On Monday - Benzinga
Immunome's desmoid tumor treatment triumphs in phase 3, setting up approval filing - Fierce Biotech
Immunome’s rare tumor drug passes Phase 3 test, could challenge Merck KGaA - Endpoints News
Immunome reports RINGSIDE trial met primary, secondary endpoints - TipRanks
Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025) - ts2.tech
Immunome Heads to the FDA With Desmoid Tumor Drug After Phase III Sweep - BioSpace
Why Is IMNM Stock Rising Today? - Stocktwits
Immunome posts Phase III success for desmoid tumour therapy - FirstWord Pharma
Immunome (IMNM) Reports Positive Phase 3 Results for Varegacesta - GuruFocus
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):